University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Int J Stroke. 2019 Dec;14(9):939-945. doi: 10.1177/1747493019851290. Epub 2019 May 23.
We aimed to evaluate the preferred treatment strategy for patients with symptomatic cerebral cavernous malformations (CCM).
In a decision model, we compared neurosurgical, radiosurgical, and conservative management. A literature review yielded the risks and outcomes of interventions, intracerebral hemorrhage (ICH), and seizures. Patients with CCM rated their quality of life to determine utilities. We estimated the expected number of quality-adjusted life years (QALYs) and the ICH recurrence risk over five years, according to mode of presentation and CCM location (brainstem vs. other). We performed analyses with a time horizon of five years.
Using the best available data, the expected number of QALYs for brainstem CCM presenting with ICH or focal neurological deficit was 2.84 (95% confidence interval [CI]: 2.54-3.08) for conservative, 3.01 (95% CI: 2.86-3.16) for neurosurgical, and 3.03 (95% CI: 2.88-3.18) for radiosurgical intervention; those for non-brainstem CCM presenting with ICH or focal neurological deficit were 3.08 (95% CI: 2.85-3.31) for conservative, 3.21 (95% CI: 3.01-3.36) for neurosurgical, and 3.19 (95% CI: 2.98-3.37) for radiosurgical intervention. For CCM presenting with epilepsy, QALYs were 3.09 (95% CI: 3.03-3.16) for conservative, 3.33 (95% CI: 3.31-3.34) for neurosurgical, and 3.27 (95% CI: 3.24-3.30) for radiosurgical intervention.
For the initial five years after presentation, our study provides Class III evidence that for CCM presenting with ICH or focal neurological deficit conservative management is the first option, and for CCM presenting with epilepsy CCM intervention should be considered. More comparative studies with long-term follow-up are needed.
我们旨在评估有症状的脑海绵状血管畸形(CCM)患者的首选治疗策略。
在决策模型中,我们比较了神经外科手术、放射外科手术和保守治疗。文献综述得出了干预措施、脑出血(ICH)和癫痫发作的风险和结果。CCM 患者评估了他们的生活质量以确定效用。根据表现形式和 CCM 位置(脑干与其他部位),我们估计了五年内的预期质量调整生命年(QALYs)数量和 ICH 复发风险。我们进行了五年时间范围内的分析。
使用最佳可用数据,对于因 ICH 或局灶性神经功能缺损而出现的脑干 CCM,保守治疗的预期 QALY 数为 2.84(95%置信区间[CI]:2.54-3.08),神经外科治疗为 3.01(95% CI:2.86-3.16),放射外科治疗为 3.03(95% CI:2.88-3.18);对于因 ICH 或局灶性神经功能缺损而出现的非脑干 CCM,保守治疗的预期 QALY 数为 3.08(95% CI:2.85-3.31),神经外科治疗为 3.21(95% CI:3.01-3.36),放射外科治疗为 3.19(95% CI:2.98-3.37)。对于因癫痫而出现的 CCM,保守治疗的 QALY 数为 3.09(95% CI:3.03-3.16),神经外科治疗为 3.33(95% CI:3.31-3.34),放射外科治疗为 3.27(95% CI:3.24-3.30)。
在出现后的最初五年内,我们的研究提供了 III 级证据,表明对于因 ICH 或局灶性神经功能缺损而出现的 CCM,保守治疗是首选,而对于因癫痫而出现的 CCM,应考虑 CCM 干预。需要更多具有长期随访的比较研究。